VOLUME 22 | NUMBER 5 | MAY 2016 nature medicine p e r s p e c t i v e
Molecular targeted therapy has the potential to dramatically improve survival in patients with cancer. However, complete and durable responses to targeted therapy are rare in individuals with advanced-stage solid cancers. Even the most effective targeted therapies generally do not induce a complete tumor response, resulting in residual disease and tumor progression that limits patient survival. We discuss the emerging need to more fully understand the molecular basis of residual disease as a prelude to designing therapeutic strategies to minimize or eliminate residual disease so that we can move from temporary to chronic control of disease, or a cure, for patients with advanced-stage solid cancers. Ultimately, we propose a shift from the current reactive paradigm of analyzing and treating acquired drug resistance to a pre-emptive paradigm of defining the mechanisms that result in residual disease, to target and limit this disease reservoir.
We live in an unprecedented era of precision medicine in which many advanced-stage solid cancers respond profoundly to therapies targeted to a specific molecular alteration that drives tumor growth [1] [2] [3] [4] [5] [6] . Prominent examples of targeted therapies include kinase inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), and ret proto-oncogene (RET) in advanced-stage lung cancer and of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and mitogen-activated protein kinase kinase 1 (MAP2K1; also known as MEK1) in advanced melanoma. The unprecedented clinical efficacy and improved safety of targeted therapies arise because these agents precisely and selectively suppress molecular events essential for tumor cell survival, with relative sparing of normal cells, in contrast to conventional cytotoxic chemotherapy approaches that target general cell-proliferative processes 5, 7 .
However, targeted therapy typically induces an incomplete tumor response that is followed by therapy-resistant tumor progression in patients with advanced-stage solid cancers (Fig. 1) 7 . The incomplete antitumor activity of many targeted therapies across different cancers has increasingly illuminated the widespread problem of residual disease. Here we define residual disease as a population of tumor cells within a mostly therapy-sensitive tumor that survives initial treatment, resulting in accumulation of a drug-resistant population that, in turn, enables eventual therapy failure and tumor progression in the presence of ongoing treatment. Consistent with the concept that this reservoir of therapy-resistant cells (hereafter referred to as residual disease cells) can ultimately drive therapy failure and tumor progression, there is a correlation in clinical trials between tumortherapy-response rates and progression-free survival for certain cancers 8 . This residual disease may either be detected early during therapy by conventional radiographic imaging showing an incomplete tumor response (Fig. 1 ) or be occult, in which case an initial complete response to the therapy is followed by eventual therapy failure and tumor progression in the presence of ongoing treatment 3 . The biological mechanisms underlying the occurrence of residual disease in patients at the time of maximal initial-therapy response remain poorly understood, mostly owing to the lack of direct analysis of samples from patients with residual disease and the lack of cancer models that faithfully recapitulate human tumor responses (with a few notable exceptions).
Understanding the biological links between an incomplete response to therapy, residual disease, and therapy-resistant tumor progression, and identifying and therapeutically targeting the residual disease cells, are essential in enhancing therapeutic responses and preventing, or minimizing, therapy failure. The incomplete therapy response, as seen in patients, has been observed in a select number of mouse solid cancer models, such as that for mouse mammary tumors that are caused by induced expression of oncogenes, including MYC, and that fail to regress completely, for unclear reasons, after de-induction of oncogene expression in vivo, resulting in residual tumor cells and tumor recurrence 9 . These data suggest that more-potent, next-generation, oncoprotein-targeted inhibitors will not be sufficient to overcome the problem of residual disease, as we discuss below.
In this Perspective, we create a framework for understanding and targeting residual disease in oncogene-driven solid cancers. We highlight the current knowledge of the etiology of clinical residual disease, which is poorly understood as compared to those of innate or acquired resistance (reviewed elsewhere 3, 7 ). We propose principled strategies to fill in the knowledge gaps of residual disease and to accelerate clinical progress through rational therapeutic strategies that directly combat the residual-disease state in oncogene-driven solid cancers-with the goal of either chronically managing or potentially eradicating disease persistence and progression. In some cases, the goal of therapies targeting residual disease will be to achieve chronic disease management, whereas in others it will be to cure disease.
The presence and etiology of residual disease Principles of residual disease. In principle, three primary types of residual disease may be linked to the incomplete response to therapy that ultimately drives residual disease and therapy-resistant tumor progression in advanced-stage solid cancers ( Fig. 1) : intrinsic resistance of tumor cell subpopulations within a generally sensitive tumor, therapy-induced adaptation of tumor cell subpopulations that enable tumor cell survival, and pharmacokinetic therapy failures that result in incomplete drug impact. Multiple mechanisms can operate within an individual metastatic tumor or between different metastatic tumors in an individual patient to promote the emergence of residual disease and therapy failure ( Figs. 1 and 2) [10] [11] [12] [13] [14] .
Intrinsic resistance. In tumor cell subpopulations within a generally sensitive tumor, intrinsic resistance can promote an incomplete response to therapy, leading to residual disease. One mechanism underlying intrinsic resistance in tumor cells is incomplete suppression of the pathway that is targeted by the signal transduction inhibitor. For example, the treatment with the targeted agent can induce rapid pathway re-activation to immediately compensate for pathway inhibition, via several mechanisms in certain cells, as observed with some BRAF inhibitors that paradoxically activate the RAF-MEK-ERK signaling pathway that they are intended to block (Fig. 2) [15] [16] [17] [18] [19] .
Tumor genetic heterogeneity is present in the treatment-naive state and manifests as both intratumoral heterogeneity, in which multiple different tumor cell clones with distinct mutational profiles exist in individual tumors, and intertumoral heterogeneity, in which there are genetic differences between different metastatic lesions. Furthermore, differences in the stromal microenvironment within an individual patient may also be substantial (such as those between the lung, the liver, and the brain) and promote residual disease 20 . Different clonal populations of cells within a metastatic tumor may harbor the relevant target of a particular drug, whereas others may not, and some may contain a drug-resistant mutant form of the target (such as the EGFR T790M mutant, which causes resistance to first-generation EGFR inhibitors) or a genetic alteration in a different target than the one affected by the drug, thereby enabling survival during therapy ( Fig. 1 ) 13, [21] [22] [23] [24] [25] [26] [27] [28] . The presence of different lineagespecific gene expression programs within tumor cell subpopulations is another form of heterogeneity that may lead to residual disease after initial rounds of therapy 29 .
Tumor cell adaptation. Tumor cell adaptation during initial treatment can promote an incomplete response and the emergence of residual disease ( Fig. 1) . Survival of these residual tumor cells can be caused by signaling or metabolic adaptations that occur either within tumor cells or within the tumor microenvironment early during the initial treatment process, permitting a drug-tolerant state in a subpopulation of tumor cells [30] [31] [32] [33] [34] . For example, EGFR-targeted therapies may elicit an epigenetically regulated 'persister' cell phenotype, and also to the adaptive activation of the transcription factor NF-κB that leads to activation of the interleukin (IL)-6-Janus kinase (JAK)-signal transducer and activation of transcription (STAT) signaling cascade, which enables survival and drug-tolerance of certain oncogene-driven lung cancer cells during initial treatments ( Fig. 2) 31, 32 . In addition to intrinsic resistance mechanisms, growth factors secreted by either tumor cells or tumor-resident stromal cells may also enable tumor cell survival during initial treatment ( Fig. 2 ) 30, 31, 35, 36 . Hence, biological events that limit targeted drug efficacy may operate across different types of residual disease, depending on the strength and kinetics of activation of the rescue signal.
Pharmacokinetic therapy failure. Pharmacokinetic therapy failure can result in residual disease, as pharmacokinetic issues that prevent the drug from sufficiently accessing all tumor cells can lead to incomplete antitumor effects [37] [38] [39] . To distinguish it from the types of residual disease discussed above, in which the targeted agent reaches the intended target in cells, this type of failure can arise owing to the presence of drug efflux pumps in tumor cells and the stromal and physical barriers that restrict drug delivery, resulting in insufficient drug concentrations to impact the intended tumor target (Fig. 1) 40, 41 . Pharmacokinetic failure due to pharmacologic limitations in drug solubility, distribution, concentration, and dose-limiting toxicity can also result in incomplete suppression of the targeted pathway, resulting in insufficient pathway blockade and residual disease in vivo 39, 42 . An example is the lack of central nervous system (CNS) penetration and activity for many agents in clinical use, including certain inhibitors of EGFR (such as erlotinib) and ALK (such as crizotinib), resulting in CNS disease persistence that is strikingly different from the extracranial tumor response (which is typically incomplete) in patients 43 .
The multifactorial basis of pharmacokinetic failure makes it a substantial challenge to the ultimate success of targeted therapy.
Targeting residual disease Several therapeutic strategies may be able to combat residual disease (Fig. 2) -including next-generation targeted therapies with activity against mutant forms of a particular oncoprotein, such as those resistant to a first-generation targeted drug; agents with favorable chemical properties, such as those that are not substrates for CNS barrier efflux pumps, and enhance CNS penetration; and rational polytherapy, which intercepts multiple survival (or anti-apoptotic) signals that enable residual disease (Fig. 2) . The diversity and heterogeneity in strategies that tumors use to evade targeted therapy emphasize the need to understand and therapeutically address this complexity to improve clinical responses. Yet, within this complexity a potential commonality across the types of failure is the apoptotic evasion of certain tumor cells in the therapeutically targeted population [10] [11] [12] [13] [14] . If confirmed in samples from patients with residual disease, then this observation suggests that a general strategy of using agents (such as inhibitors of BCL-2 anti-apoptotic protein family members 26, 44 ) that prime or lower the apoptotic threshold necessary for targeted therapy-induced tumor death, perhaps as part of a polytherapy that also includes an oncoprotein-targeting agent, should be considered.
Rational polytherapy. An emergent theme in cancer therapy is the potential for rational targeted polytherapy, rather than monotherapy, for the induction of a more complete and durable tumor response, because of the ability of polytherapy to address the diverse and multifactorial basis of therapy failure. Clinical responses to treatment with next-generation targeting agents that-unlike earlier-generation drugs-can block mutant, drug-resistant forms of the intended target remain incomplete, and acquired resistance to such newer agents often occurs earlier than that with the initial oncoprotein-targeted therapy [45] [46] [47] . One such example is the third-generation EGFR inhibitor osimertinib, which blocks the mutant protein EGFR T790M that causes resistance to the first-generation EGFR inhibitor erlotinib in lung cancer 47 . Clinical responses to osimertinib are often profound but remain incomplete, resulting in residual disease and eventual tumor progression 47 . These observations indicate diminishing returns for the use of sequential monotherapy strategies, even with improved individual targeted therapeutic agents. It is also not clear that up-front use of such next-generation inhibitors will substantially delay resistance, as use of these drugs may select for different resistance mechanisms at a similar pace. For example, use of the third-generation EGFR inhibitors may select for cells expressing the EGFR C797S resistance mutation equally as fast as the use of a first-generation EGFR inhibitor that selects for EGFR T790M (ref. 48) . Further enhancement of a clinical response will probably require rational targeted polytherapy with an agent directed against the primary tumor driver plus a drug directed against a biological event that drives residual disease.
Clinical context. Another general theme in cancer therapy is the importance of the clinical context in which therapies designed to enhance patient survival are deployed. Therapies to overcome targeted therapy resistance are typically tested in the context of a secondline treatment strategy for patients who have failed first-line treatment ( Table 1) [45] [46] [47] . However, in many cases second-line polytherapy directed against the primary oncoprotein target plus a protein that can bypass the antitumor tumor effects of the oncoprotein inhibitor has shown muted clinical efficacy, as exemplified by results from clinical trials testing a combined treatment with inibitors to both EGFR and phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3; also called PI3K) in lung cancer ( Table 1) 42, [48] [49] [50] . An example of the potential importance of using rational polytherapy as a first-line therapeutic strategy is the combined use of a BRAF inhibitor and a MEK1 inhibitor in patients with BRAF V600E melanoma to overcome the re-activation of RAF-MEK-ERK signaling that can occur during BRAF inhibitor monotherapy and cause resistance to treatment with BRAF inhibitors alone 14, 51 . Although the combined MEK inhibitor and BRAF inhibitor treatment was ineffective at overcoming acquired BRAF-inhibitor resistance 48 , up-front BRAF-MEK inhibitor polytherapy improved patient survival, as compared to BRAF inhibitor monotherapy, and elicited an improved tumor-response rate that reflects the activity of this up-front polytherapy to suppress the emergence of residual disease, consistent with the hypothesis that residual tumor cells drive disease relapse after monotherapy (in this case, with the BRAF inhibitor alone) 52, 53 . Up-front polytherapy may be able to better neutralize or eliminate the residual disease cells that fuel eventual tumor progression. Thus, the timing of the polytherapy is critical in battling residual disease and drug resistance. However, clinical responses to effective up-front polytherapy (for example, BRAF + MEK inhibition in melanoma) are still typically incomplete and not curative 52, 53 . Combining agents that induce non-overlapping mechanisms of resistance in tumors is warranted 54, 55 , but such efforts should be guided by understanding the residual disease state to define the agents that should be combined and to measure the efficacy of the polytherapy used to prevent residual disease.
Redefining the target and therapeutic landscape
We advocate caution and the careful reprioritization of strategies to enhance clinical responses to targeted therapies, given the generally incremental, rather than transformative, clinical progress than has been made to date toward the goal of turning most advanced-stage solid cancers into chronic or curable conditions. Developing better ways to prioritize therapy regimens in appropriate patient subsets, as defined by molecular criteria, is necessary to accelerate progress. Indeed, current strategies to prioritize specific therapies (or polytherapies) for clinical testing remain inadequate to support systematic clinical development of targeted polytherapies. The number of potential combination regimens vastly exceeds the number of clinical trials possible, particularly in molecular-subclass-specific trials in which only a small fraction of patients are selected for enrollment 56 . Currently, standard preclinical models, including cell lines and animal models, are used to define and prioritize most therapeautic strategies. Although these preclinical models can be useful, they lack sufficient predictive power for systematic, accurate, and effective translation into clinical application 57 . These conventional tumor models often do not accurately represent the salient features of human cancer, such as genetic heterogeneity and micro-environmental influences, and may even distort tumor-cell-signaling properties that are present in humans 58 .
A new strategy. We propose a distinct strategy to develop and prioritize treatment regimens based upon the residual state of the disease at the point of maximal therapy response in patients. This residual state would be accessed via tumor and 'liquid' (blood) biopsies 59 , and this would allow quantification and molecular definition of residual disease cells for ex vivo study (potentially leveraging single-cell analyses). It would create the opportunity for more precise and accurate understanding of residual disease and the generation of more appropriate patient-derived models, such as xenografts and organoids, for the investigation of the functional properties of residual disease 57, 60, 61 . Multimodal characterization of primary patient (and patient-derived) tumors obtained before and at the time of maximal response-using genetic, epigenetic, proteomic, and cellular phenotypic analyses to define resident tumor, stromal, and immune cell types present in the residual tumor-may provide a cohesive and complete view of the ecological properties of the residual disease
state. An open and noteworthy question to address in research studies is the feasibility of using such a process of multimodal characterization in a clinical setting. This kind of approach would enable simultaneous exploration of key open questions. Is incomplete response a consequence of genetic heterogeneity that is apparent through phylogenetic tree analysis, and, if so, to what extent 21, 62 ? Are residual cancers characterized npg by reversion to certain phylogenetic genomic events that represent early clonal drivers of oncogenesis, so-called truncal genomic alterations 21 ? To what extent does targeted therapy induce a drugtolerant epigenetic or apoptotically anergic state in residual disease cells in patients?
The relevance of immune strategies. Furthermore, the above strategy could define the contribution and biological character of stromal and infiltrating immune cells in the residual disease state 63 . Determining whether certain immune cell subsets are present and active in the tumor at the point of maximal therapeutic response of residual cancers could offer a strong biological rationale to investigate combined inhibition of certain immunosuppressive checkpoint proteins 63 , such as programmed cell death 1 (PDCD1; also called PD1; expressed on T and B cells) and CD274 molecule (also called programmed cell death 1, ligand 1 (PDL1); expressed on tumor cells), with oncoprotein-inhibitor treatment. This approach could be pursued either as a simultaneous initial polytherapy or as sequential monotherapies. A strategy in which a therapeutic response to a tumor is initially induced by treatment with an oncoprotein inhibitor, followed by augmentation or consolidation of the initial (as yet incomplete) tumor response with an immunotherapy, is attractive. This is because such a strategy might achieve a durable clinical remission with less toxicity, similar to those for certain leukemias that are treated with induction chemotherapy followed by a distinct consolidation chemotherapy regimen 64, 65 . However, characterizing the residual disease state is essential for the necessary biological foundation of such a strategy.
Indefinite versus discontinuation therapy. Finally, longitudinal biological phenotyping of residual disease during the treatment window would allow for the determination of whether continuous therapy for an indefinite amount of time is necessary for durable disease control or whether targeted therapy discontinuation can be safely recommended in select patients with advanced-stage solid cancer. Residual disease monitoring could be used to indicate sustained disease elimination or control, or to indicate the need for therapy reinitiation in such patients.
Clinical end points.
Understanding and targeting residual disease will require additional clinical metrics and end points. Current clinical end points-such as conventional radiographic response, progression-free survival, and overall survival-are inadequate measures of residual disease. We propose the use of the 'residual tumor fraction (RTF)' (Fig. 2) to quantify the residual tumor cell population that remains at the maximal treatment-response time point, which would be done by using positron-emission tomography (PET)-based, molecular-imaging probes and/or molecular phenotyping of tumor and liquid biopsies, and could accelerate studies of the residual disease state and polytherapy clinical testing 66 . This approach would enable a more precise and earlier readout of residual disease burden and characteristics, such as tumor metabolic activity or pathway signaling, in the up-front setting. For instance, measurement of nuclear NF-κB or STAT3 levels in tumor cells in a lung adenocarcinoma biopsy obtained at the time of maximal response to EGFR inhibitor treatment could offer both molecular biomarkers and therapeutic targets to quantify and eliminate residual 68, 69 . Because oncoprotein-targeted therapies have not yet transitioned from being used in the setting of metastatic disease to being incorporated into curative-intent regimens for early-stage disease, the time is ripe to establish clinical trial protocols that will achieve these dual goals. The incorporation of liquid biopsies that measure circulating tumor DNA in the blood of individuals 20,70-72 -and potentially of advanced liquid biopsy methods that reliably capture intracellular signaling events, as well as genetic mutations-into the clinical trials for metastatic cancers or neo-adjuvant therapy, could identify and monitor the key cellular and genetic features of the disease longitudinally during the course of treatment (including at incomplete maximal response), which could inform the biology of residual disease and its functional relationship to the treatment-naive and acquired-resistance states in patients with solid cancers (Fig. 2) . Efforts to understand residual disease could provide the strongest possible rationale for testing polytherapies that can have challenging toxicity. For instance, the data may offer the biological rationale for combining agents with non-overlapping toxicities or for using specific sequential or alternating drug regimens to maximize efficacy and minimize toxicity. Understanding clinical residual disease would strengthen the rationale for testing drug combinations using therapeutic agents from the portfolios of different pharmaceutical companies. The latter remains a challenge, as each company has different, and often competing, priorities for the development of individual agents that should be combined into a rational polytherapy. Data from the analysis of residual disease samples could potentially encourage inter-company collaboration.
Capturing and studying patient-derived residual disease samples faces challenges, including subjecting patients to repeat biopsies and blood tests at the time of maximal therapeutic response, obtaining material of sufficient quantity and quality for analysis, and covering the cost involved in repeating the biopsy procedure in patients. However, with the use of modern, safe tumor-sampling methods (such as image-guided biopsies) and liquid biopsies, obtaining and studying residual disease samples from patients with advanced-stage solid cancers who receive targeted therapy is feasible and can provide important insights 31 . Until the utility of repeat tumor (and blood) sampling is proven through clinical trials, the cost of such repeat tumor sampling will probably need to be covered by research programs in academic, community, and commercial (diagnostic and pharmaceutical) organizations. We believe that this cost is an invaluable investment toward the diagnostic and therapeutic advances that are necessary to substantially improve outcomes for patients and to continue to generate therapies that all stakeholders-including government and private insurance payers-will value over the longer term, as is the case now for many costly on-treatment imaging tests such as PET scans. Patient engagement is critical to the success of such an initiative and will empower the individuals who stand to benefit the most.
Future directions
We call on the research community to harness the available resources to refocus efforts to better diagnosis, monitor, and therapeutically eliminate residual disease. This new directive could catalyze a dramatic improvement in the survival of patients with solid cancers through definitive, up-front polytherapy regimens that combat residual disease and induce durable responses and potential cures.
